Research Progress of Pulmonary Extranodal Marginal Zone Lymphoma.
10.3779/j.issn.1009-3419.2024.106.31
- Author:
Shaowei ZHANG
1
Author Information
1. Department of Cardiothoracic Surgery, Pingdingshan Medical District, 989th Hospital of Joint Logistics Support Force,
Pingdingshan 467021, China.
- Publication Type:English Abstract
- Keywords:
Anti-bacterial agents;
Mucosa-associated lymphoid tissue lymphoma;
NF-κB signal pathway;
Primary pulmonary lymphoma;
Rituximab
- MeSH:
Humans;
Lymphoma, B-Cell, Marginal Zone/diagnostic imaging*;
Lung Neoplasms/diagnostic imaging*;
Prognosis;
Tomography, X-Ray Computed
- From:
Chinese Journal of Lung Cancer
2024;27(12):947-955
- CountryChina
- Language:Chinese
-
Abstract:
Mucosa-associated lymphoid tissue (MALT) lymphoma is the most common primary pulmonary lymphoma, which is an indolent B-cell lymphoma thought to originate from marginal zone B cells. Its pathophysiology is closely related to chronic antigenic stimulation, regardless of whether the antigens are auto-antigens or of microbial origin. Due to its nonspecific clinical presentation and low prevalence, pulmonary MALT lymphoma is often misdiagnosed. The disease is slow-growing, and different treatments have shown good efficacy, but its optimal treatment is somewhat controversial. This paper reviews the epidemiology, pathogenesis, clinical manifestations, computed tomography (CT) features, pathological diagnosis, treatment and prognosis of pulmonary MALT lymphoma, providing reference for clinicians to further understanding of the disease.
.
